Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis

Rhea-AI Summary

Artivion (NYSE:AORT) received U.S. FDA PMA approval for its AMDS Hybrid Prosthesis to treat acute DeBakey Type I aortic dissections with malperfusion, about 60% of such cases.

Approval removes HDE-related IRB requirements, is backed by PERSEVERE trial data, and targets a $150 million estimated annual U.S. market.

Positive

• FDA PMA approval for AMDS Hybrid Prosthesis in the United States
• Indication covers acute DeBakey Type I dissections with malperfusion, ~60% of such cases
• PERSEVERE trial showed 72% reduction in 30-day all-cause mortality vs standard hemiarch
• PERSEVERE trial showed 54% reduction in primary major adverse events vs standard hemiarch
• Zero distal anastomotic new entry (DANE) tears observed in PERSEVERE, vs estimated 45% DANE after hemiarch repair
• Estimated $150 million annual U.S. market opportunity following PMA approval

Negative

• None.

News Market Reaction – AORT

-5.17%

1 alert

-5.17% Session close to close

-14.3% Trough Tracked

$1.15B Market Cap

0.1x Rel. Volume

In the Jun 29 session, AORT declined 5.17%, reflecting a notable negative market reaction. Argus tracked a trough of -14.3% from its starting point during tracking.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -5.2% in the session following this news. A negative reaction despite positive trial...

Analysis

The stock moved -5.2% in the session following this news. A negative reaction despite positive trial results and FDA approval would fit AORT’s occasional divergence after good news, with recent insider selling and execution risk around full AMDS adoption remaining key overhangs.

Key Figures

Eligible case share: 60% of DeBakey Type I dissections Mortality reduction: 72% reduction MAE reduction: 54% reduction +5 more

8 metrics

Eligible case share 60% of DeBakey Type I dissections Acute cases with clinical or radiographic malperfusion

Mortality reduction 72% reduction All-cause mortality at 30 days in PERSEVERE U.S. IDE trial

MAE reduction 54% reduction Primary major adverse events at 30 days vs standard care

DANE tears 0 occurrences Distal anastomotic new entry tears at 30 days in PERSEVERE

Annual U.S. incidence 6,000 patients U.S. acute DeBakey Type I aortic dissection cases per year

Untreated mortality rate 1% per hour Reported mortality progression for untreated dissections

48-hour mortality 50% within 48 hours Reported untreated mortality for acute dissections

Market opportunity $150 million annually Estimated U.S. AMDS market after PMA approval

Previous Fda approval Reports

2 past events · Latest: Apr 07 (Positive)

Same Type Pattern 2 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 07	FDA device approval	Positive	+5.3%	U.S. FDA approval of the NEXUS Aortic Arch System enabling Endospan option.
Dec 09	FDA HDE approval	Positive	-2.2%	FDA Humanitarian Device Exemption for AMDS Hybrid Prosthesis with strong PERSEVERE data.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Past FDA approvals for AORT have produced mixed, generally modest single-digit price reactions.

Key Terms

pma, humanitarian device exemption, institutional review board, ide trial, +2 more

6 terms

pma regulatory

"the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA)"

PMA stands for Premarket Approval, the U.S. Food and Drug Administration’s highest-level review for high-risk medical devices. It’s a thorough evaluation to confirm a device is safe and effective before it can be sold, like a final safety inspection and license to operate. Investors care because receiving PMA can open a significant revenue stream, while delays or rejection can postpone sales and reduce a company’s value.

humanitarian device exemption regulatory

"a requirement associated with the Humanitarian Device Exemption (HDE)"

A humanitarian device exemption is a regulatory pathway that lets a medical device be approved for use in treating or diagnosing very small patient groups without the usual proof that it works as well as larger treatments; think of it as a special permit for products that serve rare conditions. It matters to investors because it can speed market access and reduce development cost, but the patient pool and sales potential are small and reimbursement or wider adoption may be uncertain.

institutional review board regulatory

"hospitals will no longer be required to obtain institutional review board (IRB) approval"

An institutional review board is an independent committee that reviews and approves research involving people to make sure studies are safe, ethical, and protect participants’ rights and privacy. For investors, IRB approval is a gatekeeper: it can determine whether a clinical trial can start or continue, affecting timelines, regulatory risk, cost and the credibility of trial results—similar to a safety inspector whose sign-off is required before work can proceed.

ide trial medical

"The PMA approval is based on data from the PERSEVERE U.S. IDE trial"

An IDE trial is a regulated clinical study that lets a company test a medical device in patients under an Investigational Device Exemption from the U.S. regulator; it’s essentially a formal permit to gather safety and effectiveness data before broad commercial approval. For investors, an IDE trial is a major de-risking step and milestone—successful results move a device closer to market approval and revenue, while delays or negative outcomes can materially affect a company’s value, similar to how a road-test permit lets a car maker prove a new model is safe before mass production.

major adverse events medical

"a 54% reduction in primary major adverse events (MAEs), including stroke, renal failure"

Major adverse events are serious, unwanted health outcomes—such as hospitalization, permanent disability, life-threatening conditions, or death—linked to a medical treatment, procedure, or product. Investors care because these events can trigger safety investigations, regulatory actions, product withdrawals, or large legal and financial liabilities; think of them as red flags that can suddenly change a company’s future sales, costs, and reputation.

malperfusion medical

"acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion"

Malperfusion is a medical condition where blood cannot reach part of the body or an organ adequately, usually because of blockage, vessel collapse, or disrupted flow — like a traffic jam that starves a neighborhood of deliveries. For investors, it matters because it drives demand for emergency care, surgeries, devices, and drugs, influences patient outcomes and hospital costs, and is often a critical endpoint in clinical trials and regulatory decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections. Given this approval, hospitals will no longer be required to obtain institutional review board (IRB) approval in order to implant AMDS in their institutions, a requirement associated with the Humanitarian Device Exemption (HDE). This will reduce administrative burden on hospitals and enabling physicians to treat eligible patients more immediately and broadly across U.S. institutions.

The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections and has been shown to significantly reduce the incidence of distal anastomotic new entry (DANE) tears. Used as a complement to hemiarch replacement without adding technical complexity, AMDS is rapidly deployed in the aortic arch during a standard ascending aorta replacement. The device preserves the native arch, enabling minimally invasive re-interventions if needed. The PMA approval is based on data from the PERSEVERE U.S. IDE trial, which at 30 days demonstrated a 72% reduction in all-cause mortality and a 54% reduction in primary major adverse events (MAEs), including stroke, renal failure requiring dialysis, and myocardial infarction, with zero occurrence of distal anastomotic new entry (DANE) tears, compared to the current standard of care hemiarch procedure. Two-year follow-up data from PERSEVERE, presented at the 62nd Annual Meeting of the Society of Thoracic Surgeons in February 2026, further demonstrate the durability of these benefits, showing minimal additional mortality limited to unrelated causes, no additional unanticipated aortic reoperation, continued absence of DANE tears, and stable total aortic diameter with continued mean true lumen diameter expansion across aortic zones 1 to 6.

Each year, approximately 6,000 patients in the U.S. present with an acute DeBakey Type I aortic dissection, an emergent, life-threatening condition requiring immediate surgical repair. Left untreated, mortality is reported to be approximately 1% per hour and up to 50% within the first 48 hours. The current standard of care, ascending replacement or hemiarch repair, can remove the primary entry tear but fails to adequately address the remainder of the diseased aorta, leaving patients at risk for complications including malperfusion, end-organ ischemia, and aneurysmal growth. Additionally, an estimated 45% of hemiarch repair patients experience DANE leading to increased risk of reoperation.

The PMA approval of AMDS, following its commercial introduction under the HDE, positions Artivion to fully penetrate the estimated $150 million annual U.S. market opportunity.

"We are thrilled to receive AMDS PMA approval, as it not only validates the enduring benefits shown in the PERSEVERE clinical data but also removes a barrier to broader adoption by eliminating the IRB requirement that came with the HDE," said Pat Mackin, Chairman, President, and Chief Executive Officer of Artivion. "Having already built commercial and clinical infrastructure during our HDE launch, and with strong reordering momentum among accounts already using AMDS, we expect this PMA to help accelerate adoption of this life saving technology."

Mr. Mackin added, "This approval, following our recent acquisition of the PMA-approved NEXUS system and continued clinical trial enrollment progress for ARCEVO LSA, marks another step forward in our vision of Artivion as the only company globally with a complete portfolio of market leading aortic arch solutions. We are deeply grateful to every PERSEVERE investigator and patient who helped make this possible."

About the AMDS PERSEVERE Clinical Trial
The PERSEVERE trial is a prospective, multicenter, non-randomized clinical trial designed to evaluate the safety and effectiveness of the AMDS Hybrid Prosthesis in patients with acute DeBakey Type I aortic dissection complicated by malperfusion. The trial consisted of 93 participants in the U.S. and was designed to support the FDA premarket approval application for AMDS. The combined 30-day safety and primary efficacy endpoints assessed the impact of AMDS on DANE, all-cause mortality, new disabling stroke, new onset renal failure requiring dialysis, and myocardial infarction. Two-year follow-up data, presented at the 62nd STS Annual Meeting in February 2026, demonstrated continued clinical and radiographic benefit with no new DANE tears, stable aortic dimensions, and no additional unanticipated aortic reoperations. Each participant will be followed for up to 5 years, with secondary endpoints related to aortic remodeling.

About the AMDS Hybrid Prosthesis and Acute DeBakey Type I Aortic Dissections
The AMDS is the world's first aortic arch remodeling device for use in the treatment of acute DeBakey Type I aortic dissections. It is used as a complement to, and in conjunction with, hemiarch replacement without adding technical complexity. The design of the AMDS allows for rapid deployment of the graft in the aortic arch during a standard replacement of the ascending aorta, with deployment adding minimal time to the procedure. Deployment of the AMDS preserves the native arch, allowing for minimally invasive re-interventions if needed rather than requiring an invasive arch repair. AMDS has been commercially available in select markets globally, including Europe, Canada, and certain countries in Asia. Aortic dissection occurs when the innermost layer of the aorta tears and blood surges through the tear, separating the layers of the aorta. In acute DeBakey Type I aortic dissections, the dissection flap originates in the ascending aorta and continues into the descending thoracic aorta. Left untreated, aortic dissections lead to death in about half of patients within the first 3 days.

About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc., is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.

Forward-Looking Statements
Statements made in this press release that look forward in time or that express management's beliefs, expectations, or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements reflect the views of management at the time such statements are made. These statements include our beliefs regarding the commercial opportunity for AMDS following PMA approval; our expectations regarding the market size for AMDS in the United States and globally; and our expectations regarding the pace of commercial expansion following PMA approval. These forward-looking statements are subject to a number of risks, uncertainties, estimates, and assumptions that may cause actual results to differ materially from current expectations, including but not limited to the risks that the benefits anticipated from the PMA approval of AMDS may not be achieved at all or at the levels anticipated; that commercial uptake of AMDS may be slower than expected; and other risk factors detailed in our Securities and Exchange Commission filings, including our most recent Form 10-K for the year ended December 31, 2025 and the Form 10-Q for the quarter ended March 31, 2026. Artivion does not undertake to update its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts: 

Artivion	Gilmartin Group LLC
Lance A. Berry	Brian Johnston
Executive Vice President	Phone: 332-895-3222
Chief Operating Officer &	investors@artivion.com
Chief Financial Officer
Phone 770-419-3355

View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-announces-us-fda-approval-of-the-amds-hybrid-prosthesis-302812309.html

SOURCE Artivion, Inc.

FAQ

What did Artivion (NYSE:AORT) announce about FDA approval of the AMDS Hybrid Prosthesis on June 29, 2026?

Artivion announced U.S. FDA PMA approval for its AMDS Hybrid Prosthesis to treat acute DeBakey Type I aortic dissections with malperfusion. According to Artivion, this approval replaces HDE status, removes IRB requirements, and supports broader AMDS adoption across U.S. hospitals.

What is the AMDS Hybrid Prosthesis and how is it used in aortic surgery?

The AMDS Hybrid Prosthesis is an aortic arch remodeling device used for acute DeBakey Type I aortic dissections. According to Artivion, AMDS complements hemiarch replacement, is rapidly deployed during standard ascending aorta replacement, preserves the native arch, and supports potential minimally invasive re-interventions.

What clinical trial results supported FDA PMA approval of Artivion’s AMDS (AORT) device?

FDA approval is supported by the PERSEVERE U.S. IDE trial in acute DeBakey Type I dissections. According to Artivion, 30-day data showed a 72% reduction in all-cause mortality, 54% reduction in primary major adverse events, and zero DANE tears versus standard hemiarch repair.

How does the AMDS Hybrid Prosthesis compare with standard hemiarch repair outcomes?

AMDS was compared with standard hemiarch repair in the PERSEVERE trial for acute DeBakey Type I dissections. According to Artivion, AMDS achieved a 72% reduction in 30-day mortality, 54% fewer major adverse events, and no DANE tears, while an estimated 45% of hemiarch patients experience DANE.

What U.S. market opportunity does Artivion see for the AMDS Hybrid Prosthesis (ticker AORT)?

Artivion estimates a significant U.S. market for AMDS in acute DeBakey Type I dissections with malperfusion. According to Artivion, PMA approval positions the company to address an estimated $150 million annual U.S. market opportunity using its existing commercial and clinical infrastructure.

How does FDA PMA approval of AMDS change hospital and patient access in the United States?

PMA approval removes the HDE-related need for institutional review board approval before AMDS implantation. According to Artivion, this reduction in administrative burden can enable physicians to treat eligible acute DeBakey Type I dissection patients more quickly and broadly across U.S. institutions.

What longer-term PERSEVERE trial outcomes support durability of the AMDS Hybrid Prosthesis?

Two-year PERSEVERE follow-up showed durability of AMDS benefits in treated patients. According to Artivion, data indicated minimal additional mortality from unrelated causes, no unanticipated aortic reoperations, continued absence of DANE tears, and stable total aortic diameter with expanding true lumen across zones 1 to 6.